Roche immunotherapy Tecentriq gains European approval for breast cancer

Roche's Tecentriq has won European approval for use against a tough-to-treat breast cancer, helping the Swiss drugmaker to widen use of an immunotherapy that has so far been eclipsed in revenue terms by more-established rival medicines.

from Reuters: Health News https://ift.tt/2Pm3xfa
https://ift.tt/xePdMM